Vanguard Global Advisers’s Neuropace NPCE Stock Holding History

Vanguard Global Advisers’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$159K	Hold	9,976	–	–	﹤0.01%	2592
2026 Q1	$131K	Buy	+9,976	New	+$150K	﹤0.01%	2613

Other funds holding NPCE

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Global Advisers's NPCE Position: Q2 2026 in Review

Vanguard Global Advisers held its Neuropace (NPCE) position steady in Q2 2026 at 9,976 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #2592.

Vanguard Global Advisers first reported a position in NPCE in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

Vanguard Global Advisers held 9,976 shares of Neuropace worth $159K as of Q2 2026.
Vanguard Global Advisers left its Neuropace share count unchanged in Q2 2026.
Neuropace made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2592 holding.
Vanguard Global Advisers first reported a position in Neuropace in Q1 2026 and has held it in 2 quarters since.
113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.